

Correction: MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas

In this article (Mol Cancer Ther 2014;13:2662–73), which appeared in the September 2014 issue of *Molecular Cancer Therapeutics* (1), the acknowledgments section was incomplete. The corrected acknowledgments section is below. The authors regret the error.

The authors thank Dr. Peter Houghton for generously providing the primary sarcoma xenografts; Dr. Dirk Mendel for insightful comments and critical review of the article; Drs. Sylvie Guichard, Teresa Klinowska, and Stephen Green from AstraZeneca's AZD2014 team for providing AZD2014 and helpful discussion; and Karen Mitz from MEDI-573 Product Development Team for reviewing the article.

Reference

1. Zhong H, Fazenbaker C, Breen S, Chen C, Huang J, Morehouse C, et al. MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas. *Mol Cancer Ther* 2014;13:2662–73.

Published online March 10, 2015.

doi: 10.1158/1535-7163.MCT-15-0014

©2015 American Association for Cancer Research.

Molecular Cancer Therapeutics

Correction: MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas

Mol Cancer Ther 2015;14:844.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/14/3/844>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://mct.aacrjournals.org/content/14/3/844.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/14/3/844>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.